Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$0.66 +7.4%	$0.52	$0.40 ▼ $2.79	$35.28M	1.14	737,976 shs	606,235 shs
ANVS Annovis Bio	$2.70 -2.6%	$2.69	$1.11 ▼ $10.54	$52.60M	1.51	459,945 shs	311,976 shs
CTMX CytomX Therapeutics	$1.77 -4.8%	$2.38	$0.40 ▼ $3.10	$142.70M	2.13	3.21 million shs	10.54 million shs
GNFT GENFIT	$3.97 +4.7%	$3.90	$2.55 ▼ $6.42	$198.51M	1.14	8,972 shs	4,666 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+0.10%	-6.96%	+27.48%	+33.89%	-75.59%
ANVS Annovis Bio	-1.95%	+1.28%	+1.65%	+62.17%	-64.87%
CTMX CytomX Therapeutics	-19.48%	-21.52%	-23.14%	-21.85%	+56.30%
GNFT GENFIT	+1.61%	+0.80%	+3.84%	-6.42%	-6.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	3.5226 of 5 stars	3.4	3.0	0.0	2.0	4.2	1.3
ANVS Annovis Bio	1.8692 of 5 stars	3.4	1.0	0.0	2.0	1.7	0.6
CTMX CytomX Therapeutics	4.0496 of 5 stars	3.5	1.0	4.7	1.7	1.7	1.3
GNFT GENFIT	1.911 of 5 stars	3.5	3.0	0.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.83	Moderate Buy	$3.30	399.55% Upside
ANVS Annovis Bio	2.75	Moderate Buy	$18.00	566.91% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	224.86% Upside
GNFT GENFIT	3.00	Buy	$13.00	227.46% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, GNFT, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
5/21/2025	ALXO ALX Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1.20 ➝ $1.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$2.14 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CTMX CytomX Therapeutics	$141.10M	1.01	$0.28 per share	6.38	$1.49 per share	1.19
GNFT GENFIT	$67.00M	2.96	$0.07 per share	53.33	$1.50 per share	2.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.47	N/A	N/A	N/A	N/A	-104.43%	-77.74%	N/A
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.56	3.16	N/A	N/A	34.04%	158.70%	36.04%	N/A
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ANVS, ALXO, GNFT, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ALXO ALX Oncology	-$0.46	-$0.49	-$0.03	-$0.49	N/A	N/A
8/12/2025	Q2 2025	ANVS Annovis Bio	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.09	5.47	5.47
ANVS Annovis Bio	N/A	10.68	10.68
CTMX CytomX Therapeutics	N/A	4.20	4.20
GNFT GENFIT	0.08	1.23	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
CTMX CytomX Therapeutics	67.77%
GNFT GENFIT	2.24%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
ANVS Annovis Bio	20.80%
CTMX CytomX Therapeutics	6.60%
GNFT GENFIT	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.40 million	42.18 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable

ANVS, ALXO, GNFT, and CTMX Headlines

Recent News About These Companies

GENFIT (NASDAQ:GNFT) Stock Price Down 3.4% - Time to Sell?

August 1, 2025 | marketbeat.com

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

July 28, 2025 | msn.com

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - The Manila Times

July 9, 2025 | manilatimes.netM

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

July 8, 2025 | globenewswire.com

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

June 17, 2025 | globenewswire.com

GENFIT S.A.: GENFIT Reports First Quarter 2025 Financial Information

May 23, 2025 | finanznachrichten.de

GENFIT Reports First Quarter 2025 Financial Information

May 22, 2025 | globenewswire.com

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

May 20, 2025 | globenewswire.com

GENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 15, 2025 | finanznachrichten.de

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 14, 2025 | globenewswire.com

Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks

May 12, 2025 | seekingalpha.com

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

May 7, 2025 | globenewswire.com

GENFIT to Present Latest ACLF Research at EASL Congress 2025

May 5, 2025 | globenewswire.com

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

April 29, 2025 | globenewswire.com

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

April 28, 2025 | globenewswire.com

GENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

April 25, 2025 | finanznachrichten.de

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

April 24, 2025 | globenewswire.com

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

March 20, 2025 | globenewswire.com

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week

March 14, 2025 | msn.com

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

March 10, 2025 | globenewswire.com

GENFIT Announces Revenues and Cash Position as of December 31, 2024

February 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, GNFT, and CTMX Company Descriptions

ALX Oncology NASDAQ:ALXO

$0.66 +0.05 (+7.40%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 +0.01 (+0.97%)

As of 05:40 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$2.70 -0.07 (-2.56%)

Closing price 03:59 PM Eastern

Extended Trading

$2.83 +0.13 (+4.71%)

As of 06:14 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

CytomX Therapeutics NASDAQ:CTMX

$1.77 -0.09 (-4.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.79 +0.02 (+1.13%)

As of 06:16 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

GENFIT NASDAQ:GNFT

$3.97 +0.18 (+4.75%)

As of 03:53 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time